The Genitourinary Cancer Channel

Explore the latest updates, including expert interviews and features

The Genitourinary Cancer Channel on VJOncology is supported by a grant from Pfizer Inc and Merck KGaA. These supporters have no influence over the production of the content.

Latest videos VJSessions Subtypes Topics Conferences Features Editorial Board

Welcome to the Genitourinary (GU) Cancer Channel!

Explore the latest updates presented at major international congresses in the form of video interviews, podcasts and roundtable discussions featuring members of our expert Editorial Board.

Exciting advances are being made in the field of genitourinary cancer, including checkpoint inhibitor treatments, new non-steroidal anti-androgens, chemoimmunotherapy combinations and predictive biomarkers.

GU Cancer Videos by Subtype

Prostate Cancer
Bladder Cancer
Kidney Cancer
Testicular Cancer
Penile Cancer
6:11
Prostate and bladder highlights at ESMO 2021
Joaquim Bellmunt • 28 Sep 2021
1:41
Survivorship challenges in advanced prostate cancer
Paul Monk • 16 Sep 2021
4:09
PSMA PET-CT scan and treatments for patients with cN1 prostate cancer
Silke Gillessen • 7 Sep 2021
2:10
Current standards for first-line metastatic hormone-sensitive prostate cancer
Paul Monk • 16 Sep 2021
View All Videos
2:36
IMvigor010 & IMvigor011: ctDNA as a response biomarker for adjuvant atezolizumab in high-risk MIBC
Joaquim Bellmunt • 28 Sep 2021
0:50
Emerging role of adjuvant immunotherapy in oncology
Joaquim Bellmunt • 28 Sep 2021
6:11
Prostate and bladder highlights at ESMO 2021
Joaquim Bellmunt • 28 Sep 2021
3:02
DANUBE: PD-L1 as a predictor of survival in patients with mUC
Joaquim Bellmunt • 28 Sep 2021
View All Videos
0:50
Emerging role of adjuvant immunotherapy in oncology
Joaquim Bellmunt • 28 Sep 2021
5:13
STAR: drug-free interval strategy for renal cell carcinoma
Janet E. Brown • 19 Sep 2021
2:40
Updates on the CABOPRE Phase II trial in patients with metastatic renal cell carcinoma
Guillermo De Velasco • 27 Sep 2021
2:20
First-line treatment decision making for patients with RCC
Guillermo De Velasco • 27 Sep 2021
View All Videos
7:05
TRISST: MRI versus FDG-PET-CT for the treatment of testicular cancer
Tahlita Zuiverloon • 15 Jul 2021
3:40
Surgery in metastatic germ cell tumors to reduce disease burden and improve long-term outcomes
Peter Albers • 8 Jul 2021
3:34
Benefits of circulating miRNAs for follow-up of patients with seminoma
Matthew Murray • 1 Jul 2021
1:12
miR-371a-3p microRNA panel alone is sufficient for diagnosis and monitoring
Matthew Murray • 1 Jul 2021
View All Videos
5:44
Long-term outcomes of DSNB for cN0 penile cancer
Edoardo Pozzi • 10 Jul 2021
2:06
c-MET receptor-targeted fluorescence for image-guided surgery in PSCC
Hielke-Martijn De Vries • 7 Jul 2021
3:14
Factors impacting additional tumour-bearing lymph nodes at completion ILND after positive DSNB
Hielke-Martijn De Vries • 7 Jul 2021
1:28
Risk factor analysis of complications after sentinel node biopsy for penile cancer
Hielke-Martijn De Vries • 7 Jul 2021
View All Videos

Topics

Trial Updates
Molecular Profiling
Immuno-Oncology
Diagnosis
Imaging
2:36
IMvigor010 & IMvigor011: ctDNA as a response biomarker for adjuvant atezolizumab in high-risk MIBC
Joaquim Bellmunt • 28 Sep 2021
0:50
Emerging role of adjuvant immunotherapy in oncology
Joaquim Bellmunt • 28 Sep 2021
5:13
STAR: drug-free interval strategy for renal cell carcinoma
Janet E. Brown • 19 Sep 2021
6:11
Prostate and bladder highlights at ESMO 2021
Joaquim Bellmunt • 28 Sep 2021
View All Videos
2:36
IMvigor010 & IMvigor011: ctDNA as a response biomarker for adjuvant atezolizumab in high-risk MIBC
Joaquim Bellmunt • 28 Sep 2021
3:02
DANUBE: PD-L1 as a predictor of survival in patients with mUC
Joaquim Bellmunt • 28 Sep 2021
2:40
Updates on the CABOPRE Phase II trial in patients with metastatic renal cell carcinoma
Guillermo De Velasco • 27 Sep 2021
2:20
Erdafitinib +/- cetrelimab in mUC patients with FGFR alterations
Yohann Loriot • 20 Sep 2021
View All Videos
2:36
IMvigor010 & IMvigor011: ctDNA as a response biomarker for adjuvant atezolizumab in high-risk MIBC
Joaquim Bellmunt • 28 Sep 2021
0:50
Emerging role of adjuvant immunotherapy in oncology
Joaquim Bellmunt • 28 Sep 2021
2:20
First-line treatment decision making for patients with RCC
Guillermo De Velasco • 27 Sep 2021
2:10
Current standards for first-line metastatic hormone-sensitive prostate cancer
Paul Monk • 16 Sep 2021
View All Videos
3:50
Detection and risk stratification of localized prostate cancer
Eugene Shenderov • 17 Sep 2021
1:12
miR-371a-3p microRNA panel alone is sufficient for diagnosis and monitoring
Matthew Murray • 1 Jul 2021
5:32
CADMUS trial: multiparametric ultrasound in prostate cancer diagnosis
Alistair Grey • 1 Jun 2021
3:01
Future research in multiparametric imaging for prostate cancer diagnosis
Alistair Grey • 1 Jun 2021
View All Videos
4:09
PSMA PET-CT scan and treatments for patients with cN1 prostate cancer
Silke Gillessen • 7 Sep 2021
3:50
Detection and risk stratification of localized prostate cancer
Eugene Shenderov • 17 Sep 2021
4:54
MGC018 in patients with advanced solid tumors
Eugene Shenderov • 17 Sep 2021
7:05
TRISST: MRI versus FDG-PET-CT for the treatment of testicular cancer
Tahlita Zuiverloon • 15 Jul 2021
View All Videos

Conferences

ESMO 2021
EAU 2021
ASCO 2021
AACR 2021
GU Cancers 2021
PROSCA/BLADDR 2020
3:45
Impacts of COVID-19 infection on patients with urological cancers undergoing surgery
Chuanyu Gao • 7 Jul 2021
3:04
Benefits of T1 substaging for NMIBC
Christiaan De Jong • 21 Jul 2021
4:19
Novel biomarkers for outcomes identified in BCG-treated T1HG bladder cancer
Christiaan De Jong • 21 Jul 2021
3:27
Improving anti-PD-1/PD-L1 therapy for localized bladder cancer
Christiaan De Jong • 21 Jul 2021
View All Videos
4:42
PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients with prostate cancer
Frédéric Pouliot • 4 Jun 2021
4:45
PrE0807: neoadjuvant nivolumab/lirilumab in cisplatin ineligible patients with MIBC
Petros Grivas • 11 Jun 2021
5:49
JAVELIN Bladder 100 trial updates from ASCO 2021
Petros Grivas • 11 Jun 2021
10:12
Trial updates in prostate cancer from ASCO 2021: VISION, PEACE1, & SWOG S1216
Pedro Barata • 8 Jun 2021
View All Videos
3:07
PSMA dRT: PSMA PET/CT before radiotherapy in prostate cancer
Jeremie Calais • 22 Apr 2021
6:49
RAMP: Phase Ib study of rucaparib & enzalutamide in mCRPC
Arpit Rao • 19 Apr 2021
4:38
Clinical utility of liquid biopsies in prostate cancer
Arpit Rao • 19 Apr 2021
3:53
Upcoming advances in prostate cancer: PARPi, CDK4/6, lutetium PSMA therapy & CAR-T approaches
Arpit Rao • 19 Apr 2021
View All Videos
1:50
Current treatment landscape of seminoma
Siamak Daneshmand • 18 Feb 2021
3:05
CA 125, CA19-9 and CEA: tumor markers in bladder cancer
Siamak Daneshmand • 18 Feb 2021
3:18
SEMS: surgery as first-line therapy for seminoma
Siamak Daneshmand • 18 Feb 2021
3:43
The history of biomarkers in the treatment of prostate cancer
Howard Scher • 18 Feb 2021
View All Videos
0:53
Immunotherapy in prostate cancer
Emmanuel Seront • 7 Oct 2020
1:35
Unmet needs in mHSPC
Ursula Vogl • 7 Oct 2020
1:29
Genomic testing in prostate cancer
Emmanuel Seront • 7 Oct 2020
0:38
Second-line treatment of mHSPC
Ursula Vogl • 7 Oct 2020
View All Videos

The GU Channel on VJOncology is supported by a grant from Pfizer Inc and Merck KGaA. The supporters have no influence over the production of the content.

If you are interested in becoming a supporter of The Genitourinary (GU) Cancer Channel, please contact us

VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals